Qi Long Lu

4.4k total citations · 3 hit papers
94 papers, 3.4k citations indexed

About

Qi Long Lu is a scholar working on Molecular Biology, Genetics and Cell Biology. According to data from OpenAlex, Qi Long Lu has authored 94 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Molecular Biology, 18 papers in Genetics and 15 papers in Cell Biology. Recurrent topics in Qi Long Lu's work include Muscle Physiology and Disorders (53 papers), Virus-based gene therapy research (16 papers) and Silk-based biomaterials and applications (10 papers). Qi Long Lu is often cited by papers focused on Muscle Physiology and Disorders (53 papers), Virus-based gene therapy research (16 papers) and Silk-based biomaterials and applications (10 papers). Qi Long Lu collaborates with scholars based in United States, United Kingdom and China. Qi Long Lu's co-authors include Terence A. Partridge, Steve D. Wilton, Peijuan Lu, Bo Wu, George Bou–Gharios, Adam Rabinowitz, HaiFang Yin, J. Alter, Fang Lou and Jeffrey Rosenfeld and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Qi Long Lu

89 papers receiving 3.3k citations

Hit Papers

Systemic delivery of morpholino oligonucleotide restores ... 2004 2026 2011 2018 2006 2004 2022 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qi Long Lu United States 28 2.9k 716 474 377 329 94 3.4k
Henry J. Klamut Canada 24 2.1k 0.7× 433 0.6× 178 0.4× 368 1.0× 461 1.4× 51 2.6k
Toshifumi Tsukahara Japan 32 3.5k 1.2× 276 0.4× 241 0.5× 458 1.2× 480 1.5× 104 4.1k
Miguel A. Esteban China 40 4.2k 1.4× 778 1.1× 280 0.6× 152 0.4× 350 1.1× 87 5.1k
Sheng Ding United States 35 3.4k 1.2× 356 0.5× 156 0.3× 140 0.4× 197 0.6× 73 4.5k
Gareth J. Sullivan Norway 27 1.9k 0.6× 209 0.3× 346 0.7× 248 0.7× 171 0.5× 68 2.9k
He Huang China 33 3.6k 1.2× 469 0.7× 144 0.3× 138 0.4× 213 0.6× 148 4.8k
Marco López-Ilasaca United States 23 1.6k 0.6× 167 0.2× 409 0.9× 343 0.9× 200 0.6× 27 2.9k
Teresa D. Gallardo United States 24 2.8k 1.0× 508 0.7× 709 1.5× 414 1.1× 162 0.5× 35 4.2k
Trond Aasen Spain 25 3.0k 1.0× 292 0.4× 200 0.4× 74 0.2× 385 1.2× 48 3.7k
Mohammadsharif Tabebordbar United States 12 2.9k 1.0× 848 1.2× 120 0.3× 337 0.9× 103 0.3× 15 3.2k

Countries citing papers authored by Qi Long Lu

Since Specialization
Citations

This map shows the geographic impact of Qi Long Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qi Long Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qi Long Lu more than expected).

Fields of papers citing papers by Qi Long Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qi Long Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qi Long Lu. The network helps show where Qi Long Lu may publish in the future.

Co-authorship network of co-authors of Qi Long Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Qi Long Lu. A scholar is included among the top collaborators of Qi Long Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qi Long Lu. Qi Long Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Bo, et al.. (2025). Ribitol treatment rescues dystroglycanopathy mice with common L276I mutation. PLoS ONE. 20(8). e0325239–e0325239.
2.
Lu, Qi Long, Xujiao Chen, & Qijun Zhang. (2024). PGC1α enhances macrophage efferocytosis in ox-LDL-stimulated RAW264.7 cells by regulating the NLRP3/PPARα axis. Tissue and Cell. 90. 102476–102476. 2 indexed citations
3.
Doddapaneni, Ravi, et al.. (2023). Metabolic Reprogramming by Ribitol Expands the Therapeutic Window of BETi JQ1 against Breast Cancer. Cancers. 15(17). 4356–4356. 2 indexed citations
5.
Lu, Qi Long. (2021). Revertant Phenomenon in DMD and LGMD2I and Its Therapeutic Implications: A Review of Study Under Mentorship of Terrence Partridge. Journal of Neuromuscular Diseases. 8(s2). S359–S367. 1 indexed citations
6.
He, Qing, et al.. (2020). First Report of Didymosphaeria rubi-ulmifolii Causing Wood Rot of Peach (Prunus persica) in China. Plant Disease. 104(9). 2525–2525. 1 indexed citations
7.
Lu, Qi Long, Fuhua Yan, Yuanyuan Liu, et al.. (2020). Comparative Genomic Analyses Reveal Functional Insights Into Key Determinants of the Pathogenesis ofPectobacterium actinidiaein Kiwifruit. Phytopathology. 111(5). 789–798. 3 indexed citations
8.
Lu, Pei, et al.. (2018). Overexpression of Mutant FKRP Restores Functional Glycosylation and Improves Dystrophic Phenotype in FKRP Mutant Mice. Molecular Therapy — Nucleic Acids. 11. 216–227. 17 indexed citations
9.
Vannoy, Charles H., et al.. (2018). Dose-Dependent Effects of FKRP Gene-Replacement Therapy on Functional Rescue and Longevity in Dystrophic Mice. Molecular Therapy — Methods & Clinical Development. 11. 106–120. 25 indexed citations
10.
Vannoy, Charles H., Will Xiao, Peijuan Lu, Xiao Xiao, & Qi Long Lu. (2017). Efficacy of Gene Therapy Is Dependent on Disease Progression in Dystrophic Mice with Mutations in the FKRP Gene. Molecular Therapy — Methods & Clinical Development. 5. 31–42. 27 indexed citations
11.
Vannoy, Charles H., Haowen Zhou, Chunping Qiao, et al.. (2017). Adeno-Associated Virus–Mediated Mini-Agrin Delivery Is Unable to Rescue Disease Phenotype in a Mouse Model of Limb Girdle Muscular Dystrophy Type 2I. American Journal Of Pathology. 187(2). 431–440. 4 indexed citations
12.
Awano, Hiroyuki, et al.. (2015). Dystroglycanopathy muscles lacking functional glycosylation of alpha-dystroglycan retain regeneration capacity. Neuromuscular Disorders. 25(6). 474–484. 6 indexed citations
13.
Wu, Bo, et al.. (2011). Targeted Skipping of Human Dystrophin Exons in Transgenic Mouse Model Systemically for Antisense Drug Development. PLoS ONE. 6(5). e19906–e19906. 15 indexed citations
14.
Wu, Bo, Bin Xiao, Caryn Cloer, et al.. (2010). One-year Treatment of Morpholino Antisense Oligomer Improves Skeletal and Cardiac Muscle Functions in Dystrophic mdx Mice. Molecular Therapy. 19(3). 576–583. 54 indexed citations
15.
Lu, Pei, Xiaohua Wu, Hanns Lochmüller, et al.. (2009). Mutations alter secretion of fukutin-related protein. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1802(2). 253–258. 14 indexed citations
16.
Lu, Pei, Timothy J. Doran, Christopher T. Esapa, et al.. (2007). Fukutin‐related protein localizes to the Golgi apparatus and mutations lead to mislocalization in muscle in vivo. Muscle & Nerve. 36(4). 455–465. 29 indexed citations
17.
Chen, Yunchao, et al.. (2005). Pluronic block copolymers: Novel functions in ultrasound-mediated gene transfer and against cell damage. Ultrasound in Medicine & Biology. 32(1). 131–137. 22 indexed citations
18.
Ma, Lan, et al.. (2000). Study on the dynamic alterations of serum HA in rats with carbon Tetrachloride-induced liver fibrosis. World Journal of Gastroenterology. 6. 100–100. 1 indexed citations
19.
Ford, Daniel Alexander, et al.. (1999). jCentral: Search the Web for Java. World Conference on WWW and Internet. 1999(1). 626–631. 2 indexed citations
20.
McGregor, Jane, et al.. (1993). Posttransplant cutaneous lymphoma. Journal of the American Academy of Dermatology. 29(4). 549–554. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026